Get started
HIMS & HERS HEALTH, INCHIMS & HERS HEALTH, INCHIMS & HERS HEALTH, INC

HIMS & HERS HEALTH, INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

HIMS chart


Full chart

Key facts today


Hims & Hers Health posted Q1 revenue of $586 million, above estimates, and adjusted EBITDA of $91.1 million. However, Q2 guidance of $530-$550 million missed expectations, causing a 6% stock drop.
Hims & Hers Health is considering two strategies: expanding its semaglutide weight loss business, potentially generating over $900 million, or reinvesting in its core operations to stabilize trends.
Analyze the impactAnalyze the impact

HIMS upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪184.61 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
61.20
Basic EPS (TTM)
15.42 MXN
Net income (FY)
‪2.63 B‬ MXN
Revenue (FY)
‪30.78 B‬ MXN
Shares float
‪183.36 M‬
Beta (1Y)
3.23

Employees


Employees (FY)
‪1.64 K‬
Change (1Y)
+591 +56.50%
Revenue / Employee (1Y)
‪18.81 M‬ MXN
Net income / Employee (1Y)
‪1.61 M‬ MXN

About Hims & Hers Health, Inc.


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Andrew Dudum
Website
forhims.com
Headquarters
San Francisco
Founded
2017
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HIMS news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as HIMS.

Frequently Asked Questions


The current price of HIMS is 973.00 MXN — it has increased by 17.43% in the past 24 hours. Watch HIMS & HERS HEALTH, INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange HIMS & HERS HEALTH, INC stocks are traded under the ticker HIMS.
HIMS stock has risen by 74.55% compared to the previous week, the month change is a 74.07% rise, over the last year HIMS & HERS HEALTH, INC has showed a 204.34% increase.
We've gathered analysts' opinions on HIMS & HERS HEALTH, INC future price: according to them, HIMS price has a max estimate of 1,673.56 MXN and a min estimate of 492.22 MXN. Watch HIMS chart and read a more detailed HIMS & HERS HEALTH, INC stock forecast: see what analysts think of HIMS & HERS HEALTH, INC and suggest that you do with its stocks.
HIMS stock is 29.41% volatile and has beta coefficient of 3.23. Track HIMS & HERS HEALTH, INC stock price on the chart and check out the list of the most volatile stocks — is HIMS & HERS HEALTH, INC there?
Today HIMS & HERS HEALTH, INC has the market capitalization of ‪184.43 B‬, it has increased by 30.78% over the last week.
Yes, you can track HIMS & HERS HEALTH, INC financials in yearly and quarterly reports right on TradingView.
HIMS & HERS HEALTH, INC is going to release the next earnings report on Aug 11, 2025. Keep track of upcoming events with our Earnings Calendar.
HIMS earnings for the last quarter are 4.10 MXN per share, whereas the estimation was 2.48 MXN resulting in a 65.41% surprise. The estimated earnings for the next quarter are 2.78 MXN per share. See more details about HIMS & HERS HEALTH, INC earnings.
HIMS & HERS HEALTH, INC revenue for the last quarter amounts to ‪12.01 B‬ MXN, despite the estimated figure of ‪11.03 B‬ MXN. In the next quarter, revenue is expected to reach ‪10.87 B‬ MXN.
HIMS net income for the last quarter is ‪1.01 B‬ MXN, while the quarter before that showed ‪542.61 M‬ MXN of net income which accounts for 86.84% change. Track more HIMS & HERS HEALTH, INC financial stats to get the full picture.
No, HIMS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 7, 2025, the company has ‪1.64 K‬ employees. See our rating of the largest employees — is HIMS & HERS HEALTH, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HIMS & HERS HEALTH, INC EBITDA is ‪2.83 B‬ MXN, and current EBITDA margin is 5.76%. See more stats in HIMS & HERS HEALTH, INC financial statements.
Like other stocks, HIMS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HIMS & HERS HEALTH, INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HIMS & HERS HEALTH, INC technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HIMS & HERS HEALTH, INC stock shows the strong buy signal. See more of HIMS & HERS HEALTH, INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.